FIELD: biotechnolgy.
SUBSTANCE: invention relates to the field of biotechnology, specifically to recombinant therapeutic proteins, and can be used in medicine for treatment of cancers of the breast, lungs, bladder, ovaries, external female genital organs, colon, pulmonary artery, brain, rectum, intestines, head , neck and esophagus. A synthetic protein based on the mutant B-subunit of the A1B5 group of bacterial holotoxins derived from the B-subunit of cholera toxin (SСT) and connected via a peptide spacer to a polypeptide including the neutralizing domain of human transforming growth factor (TGF) is proposed.
EFFECT: invention provides for production of stable homopentameric structures without loss of the function of TGF-induction of the immune response in mammalian host organisms with the formation of neutralizing antibodies against TGF.
7 cl, 6 dwg, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SELF-ASSEMBLY SYNTHETIC PROTEINS | 2014 |
|
RU2801230C2 |
| RECOMBINANT PROTEINS AND THEIR THERAPEUTIC USES | 2012 |
|
RU2650574C2 |
| RECOMBINANT PROTEINS AND THEIR APPLICATIONS IN THERAPEUTIC PURPOSES | 2018 |
|
RU2766595C2 |
| IMMUNOGENIC COMPOSITIONS AND METHODS | 2008 |
|
RU2468034C2 |
| SAPOVIRUS VACCINES | 2022 |
|
RU2839769C2 |
| IMMUNOGENIC COMPOSITIONS OF MULTIPLE ANTIGEN PRESENTATION, METHODS AND APPLICATIONS RELATING THERETO | 2012 |
|
RU2619176C2 |
| MODIFIED BIOTIN-BINDING PROTEIN, FUSION PROTEINS BASED THEREON AND THEIR APPLICATION | 2012 |
|
RU2632651C2 |
| TREATMENT OR PREVENTION OF INFECTION | 2011 |
|
RU2617399C2 |
| FMDV VACCINES BASED ON A RECOMBINANT ADENOVIRAL VECTOR AND USE THEREOF | 2017 |
|
RU2725495C2 |
| IMMUNE STIMULATING AND VACCINE COMPOSITIONS | 2011 |
|
RU2578420C2 |
